Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
WHWK Stock Chart & Stats
$3.45
--
Market closed
$3.45
--
Day’s Range― - ―
52-Week Range$1.39 - $4.48
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.35M
Market Cap
$154.80M
Enterprise Value$125.26M
Total Cash (Recent Filing)$145.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
May 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding47,196,564
10 Day Avg. Volume9,835,549
30 Day Avg. Volume3,352,856
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue17.53
Enterprise Value/Gross Profit19.64
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$6.50Price Target Upside88.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementAnalyst notes PTK7 and MUC16 programs entering the clinic, which could provide early clinical proof of concept for the company's next-generation antibody drug conjugates and validate development progress.
Platform Technology And In-licensingAnalyst points to in-licensed ADC assets built to improve linker stability, antigen internalization, and pharmacokinetics, which may translate into a wider therapeutic window and better tolerability versus older ADCs.
Preclinical Data And IND ProgressAnalyst highlights preclinical data presentations and an IND submission for a SEZ6-targeted ADC as potential catalysts that could rekindle investor interest and clarify the therapy's translational potential.
Bears Say
Clinical Safety RiskAnalyst flags safety risks from topoisomerase I-related adverse events and prior ADC toxicities, noting severe blood toxicities and lung injury could compromise development or require restrictive dosing.
Commercial Expansion RiskAnalyst warns that FYARRO could face disappointing market uptake in its niche indication or fail to expand into other cancers, which would limit potential revenue and growth opportunities.
Valuation And Coverage UncertaintyAnalyst excludes early-stage assets from valuation due to lacking clinical efficacy data, and a neutral rating without a price target underscores uncertainty around near-term valuation and investor visibility.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.39 and its highest was $4.48 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $154.80M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 36 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.483 by $0.143.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 47,196,564 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.483. Following the earnings report the stock price went down -2.743%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (88.41% Upside)
$6.50 (88.41% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.79%
12-Months-Change
Fundamentals
Return on Equity
-10.35%
Trailing 12-Months
Asset Growth
94.89%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
WHWK Stock 12 Month Forecast
Average Price Target
$6.50
▲(88.41% Upside)
Technical Analysis
Ownership Overview
26.29% Insiders
4.10% Mutual Funds
61.65% Other Institutional Investors
4.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---